{
    "id": "36335944-2d3c-b82e-e063-6294a90a705c",
    "indications": "phenytoin oral suspension indicated treatment tonic-clonic ( grand mal ) psychomotor ( temporal lobe ) seizures .",
    "contraindications": "adult starting dose patients received previous treatment 5 ml three times daily , dose adjustments necessary , 25 ml daily . ( 2.2 ) pediatric starting dose 5 mg/kg/day two three equally divided doses , adjustments necessary , maximum 300 mg daily . maintenance 4 mg/kg/day 8 mg/kg/day . ( 2.3 ) serum blood level determinations may necessary optimal adjustments—the clinically effective serum total concentration 10 mcg/ml 20 mcg/ml ( unbound phenytoin concentration 1 mcg/ml 2 mcg/ml ) . ( 2.1 )",
    "adverseReactions": "phenytoin oral suspension contraindicated patients : history hypersensitivity phenytoin , inactive ingredients , hydantoins [ ( 5.5 ) ] . included angioedema . history prior acute hepatotoxicity attributable phenytoin [ ( 5.8 ) ] . coadministration delavirdine potential loss virologic response possible resistance delavirdine class non-nucleoside reverse transcriptase inhibitors .",
    "ingredients": [
        {
            "name": "CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED",
            "code": "K679OBS311"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "MAGNESIUM ALUMINUM SILICATE",
            "code": "6M3P64V0NC"
        },
        {
            "name": "POLYSORBATE 60",
            "code": "CAL22UVI4M"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "PHENYTOIN",
            "code": "6158TKW0C5"
        }
    ],
    "organization": "ATLANTIC BIOLOGICALS CORP.",
    "name": "Phenytoin",
    "effectiveTime": "20250528",
    "indications_original": "Phenytoin oral suspension is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures.",
    "contraindications_original": "Adult starting dose in patients who have received no previous treatment is 5 mL three times daily, with dose adjustments as necessary, up to 25 mL daily. ( 2.2 ) Pediatric starting dose is 5 mg/kg/day in two to three equally divided doses, with dosage adjustments as necessary, up to a maximum of 300 mg daily. Maintenance dosage is 4 mg/kg/day to 8 mg/kg/day. ( 2.3 ) Serum blood level determinations may be necessary for optimal dosage adjustments—the clinically effective serum total concentration is 10 mcg/mL to 20 mcg/mL (unbound phenytoin concentration is 1 mcg/mL to 2 mcg/mL). ( 2.1 )",
    "adverseReactions_original": "Phenytoin oral suspension is contraindicated in patients with:\n                  \n                     A history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins\n  \n   [see\n   \n    Warnings and Precautions (5.5)].\n  \n   Reactions have included angioedema.\n \n  \n                     A history of prior acute hepatotoxicity attributable to phenytoin\n  \n   [see\n   \n    Warnings and Precautions (5.8)].\n  \n   \n                     \n                     Coadministration with delavirdine because of the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors."
}